Talphera, Inc. (NASDAQ:TLPH) Sees Large Growth in Short Interest

Talphera, Inc. (NASDAQ:TLPH) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 81,300 shares, an increase of 166.6% from the December 31st total of 30,500 shares. Approximately 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 94,900 shares, the days-to-cover ratio is currently 0.9 days.

Hedge Funds Weigh In On Talphera

An institutional investor recently bought a new position in Talphera stock. Rosalind Advisors Inc. purchased a new stake in Talphera, Inc. (NASDAQ:TLPH) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera accounts for about 0.4% of Rosalind Advisors Inc.’s holdings, making the stock its 25th largest position. Rosalind Advisors Inc. owned 4.47% of Talphera as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Stock Down 9.3 %

Talphera stock traded down $0.06 during trading hours on Friday, hitting $0.64. The stock had a trading volume of 326,375 shares, compared to its average volume of 109,909. The stock has a market cap of $10.81 million, a price-to-earnings ratio of -0.92 and a beta of 0.28. Talphera has a one year low of $0.50 and a one year high of $1.61. The business’s 50 day simple moving average is $0.65 and its 200-day simple moving average is $0.81.

Analysts Set New Price Targets

Several analysts recently weighed in on TLPH shares. Rodman & Renshaw started coverage on Talphera in a research report on Tuesday. They set a “buy” rating and a $4.00 price objective for the company. RODMAN&RENSHAW upgraded Talphera to a “strong-buy” rating in a research report on Tuesday. Maxim Group upgraded Talphera to a “strong-buy” rating in a research report on Friday, November 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Talphera in a research report on Tuesday, January 21st.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.